Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients

Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients

Background. Kidney transplantation with hepatitis C viremic (dHCV+) donors appears safe for recipients without HCV when accompanied by direct acting antiviral (DAA) treatment. However, US programs have been reluctant to embrace this approach due to concern about insurance coverage. While the cost of...

Full description

Bibliographic Details
Main Authors: David A. Axelrod, MD, MBA, Krista L. Lentine, MD, PhD, Ramji Balakrishnan, PhD, Su-Hsin Chang, PhD, Terek Alhamad, MD, Huiling Xiao, MS, Bertran L. Kasiske, MD, Roy D. Bloom, MD, Mark A. Schnitzler, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2020-12-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001056

Similar Items

Similar Items